14 November 2024

4basebio PLC

("4basebio" or the "Company")

Appointment of Joint Corporate Broker

14 November 2024 – 4basebio PLC (AIM: 4BB) (“4basebio” or the “Company”), which develops and commercialises the large scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, announces the appointment of RBC Capital Markets as the Company's joint corporate broker, to work alongside Cavendish Capital Markets, with immediate effect.

Enquiries

        4basebio PLC
                                       +44 (0)1223 967 943
Dr. Heikki Lanckriet

Joint Corporate Broker

RBC Capital Markets                    +44 (0)20 7653 4000

Rupert Walford / Kathryn Deegan

Joint Corporate Broker

Cavendish Capital Markets Limited      +44 (0)20 7220 0500

Geoff Nash / Nigel Birks

Nominated Adviser

Cairn Financial Advisers LLP           +44 (0)20 7213 0880

Jo Turner / Sandy Jamieson / Ed Downes

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.